News

Elenagen, developed by biotech firm CureLab Oncology, is designed to modulate the immune response and target cancer-associated inflammation.

Elenagen, a novel DNA immunotherapy doubles survival time for ovarian cancer patients in breakthrough Phase II study. Elenagen, a first-in-class plasmid DNA therapy (immunotherapy), in combination with standard gemcitabine chemotherapy increased median overall survival (OS) from 13 months to over 25 months in patients with tough ovarian cancers.() The data come from findings published in the International Journal of Gynecological Cancer.

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.

All received standard gemcitabine chemotherapy, and half also received elenagen, being developed by CureLab Oncology, as a once-weekly injection into the muscle.

Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say. The 30 women in the study had ovarian cancer resistant to first-line platinum-based chemo drugs, along with elevated blood levels of a cancer protein called CA-125.

Health Rounds: Experimental drug doubles survival of ovarian cancer patients in trial Feb 13 (Reuters) – Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say.

Feb 13 (Reuters) – Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say. The 30 women in the study had ovarian cancer resistant to first-line platinum-based chemo drugs, along with elevated blood levels of a cancer protein called CA-125.

Feb 13 (Reuters) – Patients with one of the deadliest gynecological cancers had dramatically improved survival when an experimental drug was added to treatment with a standard chemotherapy medication in a mid-stage trial in Belarus, researchers say. The 30 women in the study had ovarian cancer resistant to first-line platinum-based chemo drugs, along with elevated blood levels of a cancer protein called CA-125.